Release Date: April 30, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Butterfly Network Inc BFLY reported a 25% revenue growth year-over-year, indicating strong financial performance.
- The company achieved a 69% gross margin, showcasing efficient cost management and profitability.
- Butterfly Network Inc (BFLY) has the lowest first-quarter net loss since going public, reflecting improved financial health.
- The company received FDA clearance for a blind sweep AI tool, enhancing its product offerings and market credibility.
- Butterfly Network Inc (BFLY) is expanding its partnerships, with two new partners joining the Butterfly Garden, increasing the portfolio to 30.
Negative Points
- The company faces risks and uncertainties related to forward-looking statements, which could impact future performance.
- There is a reliance on regulatory approvals, which can be uncertain and time-consuming.
- Butterfly Network Inc (BFLY) is investing heavily in new areas, which may not yield immediate returns and could affect short-term profitability.
- The company is navigating a complex global macroeconomic environment, including potential impacts from the war in the Middle East and tariffs.
- Despite progress, the company still reported an adjusted EBITDA loss of $6.1 million for the first quarter of 2026.
Q & A Highlights
Q: Can you speak about the progress made with medical schools in the second quarter and how it compares to prior years?
A: Joseph DeVivo, CEO: The second quarter is typically our biggest for medical schools due to their fiscal year ending on June 30. We had a good first quarter and expect a very positive second quarter. Our goal is to convince every medical student to have their own probe, which could double our sales annually.
Q: Can you provide more details on the Compass AI Enterprise deal and its potential impact on revenue this year?
A: Joseph DeVivo, CEO: Our pipeline has seen a sharp increase, indicating strong enterprise sales potential. We expect this to be a very good year for enterprise deals and Compass AI, as we've made the platform easier for clinicians and faster for documentation.
Q: Can you provide more insight into the Butterfly Embedded partnerships and their potential impact?
A: Joseph DeVivo, CEO: Each new partner represents an opportunity to develop a new market segment. While some partners are in early stages, others could have a significant near-term financial impact similar to the Midjourney deal. These partnerships could lead to exclusive use cases and significant leverage for Butterfly.
Q: How do you envision the home and community care channel playing out over the next 6 to 24 months?
A: Joseph DeVivo, CEO: We are moving from a feasibility pilot to a commercial agreement, aiming to show operational and economic benefits in one state this year. If successful, we plan to expand to more states and nationwide in 2027, significantly reducing healthcare costs and improving patient care.
Q: Can you discuss the impact of the FDA clearance of the gestational AI tool on future AI tools and partnerships?
A: Joseph DeVivo, CEO: The FDA clearance validates our rigorous approach to AI tool development, setting a high standard for future tools. This has piqued interest from partners and ministries of health, potentially leading to large deployments and revenue growth, especially in developing countries.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
